Inozyme Pharma up as mineralization disorder drug shows promise

Inozyme Pharma

04/04/2022 13:27

** Biopharmaceutical company's shares  INZY.O  up 11.4% at
$4.20 premarket
    ** Company reports positive preliminary data from ongoing
early-stage study of its experimental therapy, INZ-701, to treat
ENPP1 deficiency, a rare mineralization disorder  urn:newsml:reuters.com:*:nFWN2W20PU
    ** ENPP1 deficiency is a genetic in-born metabolism error
caused by mutations in ENPP1 gene
    ** All three patients dosed so far in first arm of trial
showed rapid, significant and sustained increases in levels of
PPi, a key predictive biomarker of therapeutic benefit in ENPP1
deficiency, according to the company
    ** Patients received 0.2 mg/kg doses and dosing is underway
at the 0.6 mg/kg dose level in second arm of trial
    ** Inozyme plans to report topline data from ongoing trial
in H2 of 2022
    ** Stock down ~45% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325))